查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球心血管超音波系统市场-2023-2030
市场调查报告书
商品编码
1374787

全球心血管超音波系统市场-2023-2030

Global Cardiovascular Ultrasound System Market -2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

心血管超音波系统也称为超音波心动图系统，是一种医学影像设备，用于对体内心臟和血管进行非侵入性评估和可视化。它利用高频声波（超音波）创建心臟结构、功能和血流模式的即时影像和视讯。这项技术对于诊断和监测各种心血管疾病至关重要，例如心臟瓣膜疾病、先天性心臟缺陷、心肌疾病、血管异常等。

心臟超音波检查应使用低频探头进行，该探头占地面积小，可安装在肋骨之间，并使用心臟设定。超音波的定义是频率大于 20,000 赫兹 (Hz)。超音波探头透过身体发送声波，患者听不到或感觉不到。当声波从内部结构反弹时，该技术解释返回波的「迴声」并即时重建患者心臟的动态影像。

市场动态：驱动因素

对先进心血管超音波系统的需求不断增加

对先进心血管超音波系统的需求不断增长预计将在预测期内推动市场发展。先进的系统包括人工智慧功能，可透过执行微创手术来改善患者的治疗效果。这些先进的系统有助于临床医生获得更快、更可重复的测试。

例如，2023 年 8 月 25 日，西门子 Healthineers 推出了 Acuson Origin，这是一款专用心血管超音波系统，具有全新、强大的人工智慧 (AI) 功能。 Acuson Origin 旨在改善患者治疗效果并帮助医生更有效地进行微创心臟手术，解决心血管患者护理的整个连续过程，包括诊断、结构性心臟、电生理和儿科手术。

此外，2020 年10 月12 日，GE Healthcare 为其Vivid 心血管超音波系统Ultra Edition 套装发布了美国FDA 510k 许可，其中包括基于人工智慧(AI) 的新功能，使临床医生能够持续获得更快、更可重复的检查。

此外，超音波技术的不断进步导致了更先进、更复杂的心血管超音波系统的发展。这些系统提供更高的影像品质、更高的诊断准确性以及增强的功能，例如 3D 和 4D 成像、应变成像和对比度增强成像。这些创新使有效诊断和治疗心血管疾病变得更加容易。

例如，2023 年 1 月 22 日，飞利浦在全球推出了下一代紧凑型心血管便携式超音波解决方案 Compact 5000 系列。这种新型超音波设备具有便携性和多功能性，且不会影响影像品质或性能，旨在为更多患者带来与优质推车超音波系统相关的诊断品质。

此外，先进的设备有助于提供增强的影像品质和便利性。例如，2021 年9 月30 日，全球医疗设备公司、三星电子子公司Samsung Medison 推出了V8，这是一款新型高级心臟病超音波系统，可为所有医疗专业人员提供增强的影像品质、可用性和便利性。

此外，心血管疾病盛行率的增加、FDA 批准的增加、对非侵入性诊断方法的需求不断增加、新系统开发中意识的提高和技术进步是预计在预测期内推动市场的因素。

限制

与机器相关的併发症、心血管超音波系统的高成本以及缺乏训练有素的专业人员等因素预计将阻碍市场的发展。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按类型分類的片段
  • 技术片段
  • 可移植性片段
  • 最终使用者的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 对先进心血管超音波系统的需求不断增长
    • 限制
      • 设备成本高
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 专利分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按类型

  • 负荷超音波心臟检查
  • 经食道心臟超音波
  • 经胸超音波心臟检查
  • 超音波心臟检查对比
  • 多普勒超音波心臟检查
  • 其他的

第 8 章：按技术

  • 二维超音波
  • 3D超音波
  • 4D超音波
  • 其他的

第 9 章：透过可移植性

  • 便携的
  • 手持式

第 10 章：最终用户

  • 医院
  • 专科诊所
  • 心血管诊断中心
  • 其他的

第 11 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 12 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 13 章：公司简介

  • Siemens Healthineers AG
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Koninklijke Philips NV
  • GE HealthCare
  • Hitachi, Ltd.
  • CANON MEDICAL SYSTEMS CORPORATION
  • ESAOTE SPA
  • SAMSUNG HEALTHCARE
  • Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
  • FUJIFILM Holdings Corporation
  • Whale Imaging Inc.

第 14 章：附录

简介目录
Product Code: MD7197

Overview

A cardiovascular ultrasound system also known as an echocardiography system is a medical imaging device used for non-invasive assessment and visualization of the heart and blood vessels within the body. It employs high-frequency sound waves (ultrasound) to create real-time images and videos of the heart's structure, function, and blood flow patterns. This technology is essential for diagnosing and monitoring various cardiovascular conditions, such as heart valve diseases, congenital heart defects, heart muscle disorders, vascular abnormalities and others.

Cardiac ultrasound should be performed with a low-frequency probe that has a small footprint that can fit between the ribs, using a cardiac setting. Ultrasound is defined as a frequency greater than 20,000 Hertz (Hz). The ultrasound probe sends sound waves, which the patient does not hear or feel, through the body. When the sound waves bounce off internal structures, the technology interprets the "echos" of the returning waves and reconstructs a moving picture of the patient's heart in real-time.

Market Dynamics: Drivers

Increasing demand for advanced cardiovascular ultrasound systems

The increasing demand for advanced cardiovascular ultrasound systems is expected to drive the market over the forecast period. The advanced systems include artificial intelligence features that are responsible for better patient outcomes by performing minimally invasive procedures. These advanced systems helps to enable clinicians to acquire faster and more repeatable tests.

For instance, on August 25, 2023, Siemens Healthineers launched the Acuson Origin, a dedicated cardiovascular ultrasound system with new, robust artificial intelligence (AI) features. Designed to improve patient outcomes and help physicians perform minimally invasive cardiac procedures more efficiently, the Acuson Origin addresses the entire continuum of cardiovascular patient care, including diagnostic, structural heart, electrophysiological, and pediatric procedures.

Additionally, on October 12, 2020, GE Healthcare released U.S. FDA 510k clearance for its Ultra Edition package on Vivid cardiovascular ultrasound systems, which includes new features based on artificial intelligence (AI) that enable clinicians to acquire faster, more repeatable exams consistently.

Moreover, ongoing advancements in ultrasound technology have led to the development of more advanced and sophisticated cardiovascular ultrasound systems. These systems offer higher image quality, improved diagnostic accuracy, and enhanced features such as 3D and 4D imaging, strain imaging, and contrast-enhanced imaging. These innovations make it easier to diagnose and treat cardiovascular conditions effectively.

For instance, on January 22, 2023, Philips launched globally their next-generation compact cardiovascular portable ultrasound solution, the Compact 5000 Series. This new ultrasound is designed for portability and versatility without compromising image quality or performance and aims to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients.

In addition, the advanced devices helps to provide enhanced image quality and convenience. For instance, on September 30, 2021, Samsung Medison, a global medical equipment company and an affiliate of Samsung Electronics, introduced the V8, a new premium cardiology ultrasound system that provides enhanced image quality, usability, and convenience for all medical professionals.

Further, the increasing prevalence of cardiovascular conditions, rising FDA approvals, rising demand for non-invasive diagnostic methods, increasing awareness and technological advancements in the development of novel systems are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the machines, the high cost of the cardiovascular ultrasound systems and lack of trained professionals are expected to hamper the market.

Segment Analysis

The global cardiovascular ultrasound system market is segmented based on type, technology, portability, end-user and region.

The transesophageal echocardiogram segment accounted for approximately 46.2% of the cardiovascular ultrasound system market share

The transesophageal echocardiogram segment is expected to hold the largest market share over the forecast period. A transesophageal echocardiogram is valuable for diagnosing conditions that may not be adequately visualized with other tests, and it is often used in cases of suspected infective endocarditis, aortic dissection, or complex valve pathology. The transesophageal echocardiography system is mainly used to manage and guide care for many cardiovascular patients.

For instance, on June 30, 2022, Clarius Mobile Health and ImaCor Inc. announced a partnership and launched a handheld transesophageal echocardiography (TEE) system designed to manage and guide care for the most critically ill patients in the Intensive Care Unit (ICU).

Moreover, a transesophageal echocardiogram shows a detailed view of the heart's structure and function. It can help diagnose and manage many different cardiovascular conditions. The transesophageal echocardiogram uses transesophageal echocardiography for the diagnosis and management of many diseases.

In May 2022, Philips announced the international launch of EchoNavigator 4.0, EPIQ CVXi interventional cardiology ultrasound system. By integrating real-time transoesophageal echocardiography (TEE), which places the ultrasound transducer close to the heart, and X-ray fluoroscopy, EchoNavigator 4.0 helps interventional teams to decide, guide, treat, and confirm complex structural heart disease therapy, such as heart valve repair or replacement.

Geographical Analysis

North America accounted for approximately 39.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and technological advancements. North America especially the United States is very well known for its strong presence of major players such as pharmaceutical companies and medical device companies. The presence of major players actively performing in research activities, leads to the launch of advanced cardiovascular ultrasound systems with better features.

For instance, on August 25, 2023, GE HealthCare launched the Vscan Air SL, a handheld, wireless ultrasound imaging system designed for rapid cardiac and vascular assessments at the point of care to help clinicians accelerate diagnoses and treatment decisions. The latest addition to the Vscan product suite, Vscan Air SL features GE HealthCare's proprietary SignalMax and Xdclear technology that provide high levels of penetration, resolution, and sensitivity in imaging performance with an industry-leading single crystal transducer technology.

Furthermore, the technological advancements in the region is also a considerable factor in the region. North America is home to several universities and research institutions that collaborate with the healthcare industry. These collaborations lead to the development of technologically innovative cardiovascular ultrasound systems, which increases the knowledge about their benefits, leading to market dominance in the region.

Competitive Landscape

The major global players in the cardiovascular ultrasound system market include: Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare, Hitachi, Ltd., CANON MEDICAL SYSTEMS CORPORATION, ESAOTE SPA, SAMSUNG HEALTHCARE, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., FUJIFILM Holdings Corporation, Whale Imaging Inc. and among others.

Key Developments

  • On June 23, 2023, UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial intelligence, released the announcement about the partnership with point-of-care ultrasound innovator EchoNous, to enable more healthcare professionals to perform cardiac ultrasound and help increase patient access to cardiac care. The new collaboration was announced at ASE 2023, the premier event for bringing together echo professionals.
  • On January 27, 2023, FUJIFILM Sonosite, Inc., specialists in developing cutting-edge point-of-care ultrasound (POCUS) solutions, and part of the larger Fujifilm Healthcare portfolio, launched the new Sonosite PX ultrasound system. Sonosite PX is the next generation in Sonosite POCUS, with the most advanced image clarity ever seen in a Sonosite system, a suite of workflow efficiency features, and an adaptable form factor.
  • In April 2022, FUJIFILM Sonosite, Inc. launched a new T8-3 transesophageal transducer and Cardiac Resuscitation exam type, to assist clinicians in using transesophageal ultrasound (TEU) at the point of care.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global cardiovascular ultrasound system market. During the early stages of the pandemic, many healthcare facilities postponed or canceled elective medical procedures, including non-urgent cardiac imaging tests such as cardiovascular ultrasounds. This led to a temporary decline in the demand for cardiovascular ultrasound systems. The pandemic also disrupted the supply chain of these devices globally.

Why Purchase the Report?

  • To visualize the global cardiovascular ultrasound system market segmentation based on type, technology, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of cardiovascular ultrasound system market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global cardiovascular ultrasound system market report would provide approximately 69 tables, 71 figures, and 188 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Portability
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Advanced Cardiovascular Ultrasound Systems
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of the Equipment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Stress Echocardiogram*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Transesophageal Echocardiogram
  • 7.4. Transthoracic Echocardiogram
  • 7.5. Contrast Echocardiogram
  • 7.6. Doppler Echocardiogram
  • 7.7. Others

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. 2D Ultrasound*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. 3D Ultrasound
  • 8.4. 4D Ultrasound
  • 8.5. Others

9. By Portability

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
    • 9.1.2. Market Attractiveness Index, By Portability
  • 9.2. Portable*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Handheld

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Cardiovascular Diagnostic Centers
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.6.1. U.S.
      • 11.2.6.2. Canada
      • 11.2.6.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.6.1. Germany
      • 11.3.6.2. UK
      • 11.3.6.3. France
      • 11.3.6.4. Italy
      • 11.3.6.5. Spain
      • 11.3.6.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.6.1. Brazil
      • 11.4.6.2. Argentina
      • 11.4.6.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.6.1. China
      • 11.5.6.2. India
      • 11.5.6.3. Japan
      • 11.5.6.4. Australia
      • 11.5.6.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Siemens Healthineers AG*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Koninklijke Philips N.V.
  • 13.3. GE HealthCare
  • 13.4. Hitachi, Ltd.
  • 13.5. CANON MEDICAL SYSTEMS CORPORATION
  • 13.6. ESAOTE SPA
  • 13.7. SAMSUNG HEALTHCARE
  • 13.8. Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
  • 13.9. FUJIFILM Holdings Corporation
  • 13.10. Whale Imaging Inc.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us